jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Article

Research on Pharmaceutical Product Life Cycle Management Challenges Faced by Generic Manufacturers for US Approval

Murthannagari Vivek Reddy1, Gonna Nandhi Krishnan Ganesh1★, Syed Suhaib Ahmed2, Praharsh Kumar Mandadhi Rajendra2, Eknath Babu3★ Corresponding author

  1. 1Department of Regulatory Affairs, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.
  2. 2Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.
  3. 3Department of Regulatory Affairs, Generic Research and Development, Micro Labs Limited, Bangalore, Karnataka, INDIA.

CORRESPONDENCE

Gonna Nandhi Krishnan Ganesh

Department of Regulatory Affairs, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, INDIA.

gnk@jssuni.edu.in

Received: 02-06-2021; Revised: 31-12-2021; Accepted: 01-04-2022.

Volume 56, Issue 2S · pp. S347–S355 · PUBLISHED 2022 · DOI: 10.5530/ijper.56.2s.105

View on IJPER original site ↗

ABSTRACT

Introduction: Generic drug approval before patent expiration involves patent infringement petitions due to robust Life Cycle Management (LCM) strategies followed by Branded companies. They will extend the patent period of a product after expiration through Exclusivity rights, which act as a barrier for generic companies to launch the product immediately after patent expiration. This study focused on United States (US) generic market. Materials and Methods: The research was conducted on three major aspects where generic companies are facing major issues they are, Patent and Exclusivities, Paragraph IV certifications and Emerging Therapeutic areas. We performed a case study by statistical analysis on 2633 US-approved generic drugs on 12 pharma companies in India from 2009 to 2020. Results: In patent litigations, we found that Indian companies have the highest number of patent litigations related to secondary patents and new clinical indication exclusivity. In Paragraph IV certifications the Indian companies share was raised to 18%. A parallel study conducted on changes in therapeutic areas of these generic drugs from the past decade revealed that the production of cancer drugs was increased compared to cardiovascular and central nervous system drugs. Conclusion: This study will help in overcoming the above issues, where we explored the knowledge gaps between generic companies and branded companies that are needed to be addressed for successful marketing of generic drugs.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Reddy, M. V., Ganesh, G. N. K., Ahmed, S. S., Rajendra, P. K. M., & Babu, E. (2022). Research on Pharmaceutical Product Life Cycle Management Challenges Faced by Generic Manufacturers for US Approval. Indian Journal of Pharmaceutical Education and Research, 56(2S), S347–S355. https://doi.org/10.5530/ijper.56.2s.105